Key regions: United Kingdom, Brazil, Europe, France, Canada
The demand for Anti-Fibrinolytic Drugs in the EAEU region has been steadily increasing over the past few years.
Customer preferences: Patients suffering from excessive bleeding due to trauma, surgery, or genetic disorders are the primary customers of Anti-Fibrinolytic Drugs. These drugs are also used to treat conditions such as menorrhagia, hemophilia, and gastrointestinal bleeding. Patients prefer these drugs as they are effective in controlling bleeding and have fewer side effects compared to other drugs.
Trends in the market: Russia is the largest market for Anti-Fibrinolytic Drugs in the EAEU region. The market has been growing due to the increase in the number of surgeries, trauma cases, and genetic disorders. The demand for these drugs is also increasing due to the aging population and the rise in lifestyle-related diseases. Kazakhstan is another major market for Anti-Fibrinolytic Drugs in the region. The market has been growing due to the increase in the number of surgeries, trauma cases, and the government's focus on improving healthcare infrastructure.
Local special circumstances: In Russia, the government has been focusing on improving healthcare infrastructure and increasing access to healthcare services. The government has also been promoting the use of generic drugs, which has led to the growth of the Anti-Fibrinolytic Drugs market. In Kazakhstan, the government has been investing in healthcare infrastructure and promoting medical tourism, which has led to an increase in the number of surgeries and trauma cases.
Underlying macroeconomic factors: The growth of the Anti-Fibrinolytic Drugs market in the EAEU region is driven by the underlying macroeconomic factors such as the increase in healthcare spending, the rise in lifestyle-related diseases, and the aging population. The region's GDP has been growing, which has led to an increase in disposable income and healthcare expenditure. The rise in medical tourism and the government's focus on improving healthcare infrastructure have also contributed to the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
